Probucol combined with valsartan in immunoglobulin <scp>A</scp> nephropathy: A multi‐centre, open labelled, randomized controlled study

Ye, Zhiming; Zhang, Li; Xu, Lixia; Shi, Wei; Hu, Haitang; Shi, Xingming; Zhong, Weide; Hou, Shuan; Yan, Hong‐Hong; Zhang, Bin; Xia, Yunlong; Wang, Wenjian; Feng, Zonglin; Wang, Liping; Liang, Yanling

doi:10.1111/nep.12177

Cited by 4 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To be mentioned, the traditional Chinese medicine, such as A. manihot and Yi‐Qi‐Qing‐Jie Formula Decoction, is increasing evaluated to reduce the adverse effect of immunosuppressive therapy in IgAN. However, except for the reported effect of fish oil in regulating expressions of important oxylipin metabolic genes in peripheral blood mononuclear cells and the effect of probucol in reducing proteinuria, the rest of the RCT mentioned above are still on the stage of recruiting or not posted the results yet. The fulfilment of these studies would provide us more therapeutic options in IgAN in the future.…”

Section: Othersmentioning

confidence: 99%

Update on treatment of immunoglobulin A nephropathy

Zhang

2018

Nephrology

View full text Add to dashboard Cite

Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and the most common cause of end‐stage renal disease in young adults. However, there are still no specific therapies capable of targeting key pathways involved in disease pathogenesis. Recently, many large randomized controlled trials have been reported, such as Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy, Targeted‐release Budesonide Versus Placebo in Patients with IgA Nephropathy and Therapeutic Evaluation of Steroids in IgA Nephropathy Global, which are considered to update the 2012 Kidney Disease: Improving Global Outcomes Guideline. More importantly, with a deeper understanding of the roles of mucosal immunity, B‐cell activation and complement activation in IgAN, the studies of targeting pathogenic pathways are ongoing. In this review, by systemically searching the clinical trials in IgAN on http://clinicaltrials.gov (https://clinicaltrials.gov/), we update the evidence for corticosteroids/immunosuppressive therapy in IgAN and explore the promising targeting pathogenic pathway therapeutic options. With better understanding of pathogenesis of IgAN, emerging therapies will soon become a reality in future.

show abstract

Section: Othersmentioning

confidence: 99%